Plasma glycine and serine levels in schizophrenia compared to normal controls and major depression: Relation to negative symptoms

International Journal of Neuropsychopharmacology

Volumn 7, Issue 1, 2004, Pages 1-8

  Sumiyoshi, Tomiki ^a,b   Anil, A Elif ^a,c   Jin, Dai ^a   Jayathilake, Karu ^a   Lee, Myung ^a   Meltzer, Herbert Y ^a,d  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TOYAMA   (Japan)

^c HACETTEPE UNIVERSITY   (Turkey)

^d Psychiatric Hospital at Vanderbilt   (United States)

Author keywords

Amino acids; Glutamate; Glycine; Negative symptoms; NMDA; Schizophrenia; Serine

Indexed keywords

AMINO ACID; GLUTAMATE RECEPTOR; GLYCINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; SERINE;

ADULT; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DEPRESSION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RATING SCALE; SCHIZOPHRENIA; SCORING SYSTEM;

ADULT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEPRESSIVE DISORDER, MAJOR; FEMALE; GLYCINE; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SERINE;

EID: 1942539345     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1461145703003900     Document Type: Article

References (49)

1. APA (1987). DSM-III-R: Diagnostic and Statistical Manual of Mental Disorders (3rd edn, rev). Washington, DC: American Psychiatric Association.
2. Baruah S, Waziri R, Hegwood TS, Mallis LM (1991). Plasma serine in schizophrenics and controls measured by gas chromatography-mass spectrometry. Psychiatry Research 37, 261-270.
3. Baruah S, Waziri R, Sherman A (1993). Neuroleptic effects on serine and glycine metabolism. Biological Psychiatry 34, 544-550.
4. Cohen J (1977). Statistical Pozoer Analysis for the Behavioral Sciences - Revised Edition. London: Academic Press.
5. Coyle JT (1996). The glutamatergic dysfunction hypothesis for schizophrenia. Harvard Review Psychiatry 3, 241-253.
6. D'Souza DC, Gil R, Cassello K, Morrissey K, Abi-Saab D, White J, Sturwold R, Bennett A, Karper LP, Zuzarte E, Charney DS, Krystal JH (2000). IV glycine and oral D-cycloserine effects on plasma and CSF amino acids in healthy humans. Biological Psychiatry 47, 450-462.
7. Endicott J, Spitzer RL (1978). A diagnostic interview: the schedule for affective disorder and schizophrenia. Archives of General Psychiatry 35, 837-844.
8. Evins AE, Amico E, Posever TA, Toker R, Goff DC (2002). D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia. Schizophrenia Research 56, 19-23.
9. Evins AE, Amico ET, Shih V, Goff DC (1997). Clozapine treatment increases serum glutamate and aspartate compared to conventional neuroleptics. Journal of Neural Transmission 104, 761-766.
10. Farber NB, Newcomer JW, Olney JW (1999). Glycine agonists: what can they teach us about schizophrenia? Archives of General Psychiatry 56, 13-17.
11. Fekkes D, Pepplinkhuizen L, Verheij R, Bruinvels J (1994). Abnormal plasma levels of serine, methionine, and taurine in transient acute polymorphic psychosis. Psychiatry Research 51, 11-18.
12. Goff DC, Coyle JT (2001). The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. American Journal of Psychiatry 158, 1367-1377.
13. Goff DC, Henderson DC, Evins AE, Amico E (1999a). A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia. Biological Psychiatry 45, 512-514.
14. Goff DC, Tsai G, Levitt J, Amico E, Manoach D, Schoenfeld DA, Hayden DL, McCarley R, Coyle JT (1999b). A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Archives of General Psychiatry 56, 21-27.
15. Goff DC, Tsai G, Manoach DS, Coyle JT (1995). Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. American Journal of Psychiatry 152, 1213-1215.
16. Goff DC, Tsai G, Manoach DS, Flood J, Darby DG, Coyle JT (1996). D-cycloserine added to clozapine for patients with schizophrenia. American Journal of Psychiatry 153, 1628-1630.
17. Goff DC, Wine L (1997). Glutamate in schizophrenia: clinical and research implications. Schizophrenia Research 27, 157-168.
18. Hagenfeldt L, Bjerkenstedt L, Edman G, Sedvall G, Wiesel FA (1984). Amino acids in plasma and CSF and monoamine metabolites in CSF: interrelationship in healthy subjects. Journal of Neurochemistry 42, 833-837.
19. Hamilton M (1960). A rating scale of depression. Journal of Neurology, Neurosurgery and Psychiatry 23, 56-62.
20. Heresco-Levy U, Ermilov M, Shimoni J, Shapira B, Silipo G, Javitt DC (2002). Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. American Journal of Psychiatry 159, 480-482.
21. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Horowitz A, Kelly D (1996). Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. British Journal of Psychiatry 169, 610-617.
22. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M (1999). Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Archives of General Psychiatry 56, 29-36.
23. Javitt DC, Zukin SR (1991). Recent advances in the phencyclidine model of schizophrenia. American Journal of Psychiatry 148, 1301-1308.
24. Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U, Lindenmayer JP (1994). Amelioration of negative symptoms in schizophrenia by glycine. American Journal of Psychiatry 151, 1234-1236.
25. Jentsch JD, Roth RH (1999). The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20, 201-225.
26. Leiderman E, Zylberman I, Zukin SR, Cooper TB, Javitt DC (1996). Preliminary investigation of high-dose oral glycine on serum levels and negative symptoms in schizophrenia: an open-label trial. Biological Psychiatry 39, 213-215.
27. Lucca A, Cortinovis S, Lucini V (1993). Serine and glycine metabolism in schizophrenic patients. Progress in Neuropsychopharmacology and Biological Psychiatry 17, 947-953.
28. Macciardi F, Lucca A, Catalano M, Marino C, Zanardi R, Smeraldi E (1990). Amino acid patterns in schizophrenia: some new findings. Psychiatry Research 32, 63-70.
29. Maes M, De Backer G, Suy E, Minner B (1995). Increased plasma serine concentrations in depression. Neuropsychobiology 31, 10-15.
30. McGale EH, Pye IF, Stonier C, Hutchinson EC, Aber GM (1977). Studies of the inter-relationship between cerebrospinal fluid and plasma amino acid concentrations in normal individuals. Journal of Neurochemistry 29, 291-297.
31. Overall JE, Gorham DR (1962). The brief psychiatric rating scale. Psychological Reports 10, 799-812.
32. Pepplinkhuizen L, Bruinvels J, Blom W, Moleman P (1980). Schizophrenia-like psychosis caused by a metabolic disorder. Lancet 1, 454-456.
33. Perry TL, Hansen S (1985). Interconversion of serine and glycine is normal in psychotic patients. Psychiatry Research 15, 109-113.
34. Potkin SG, Jin Y, Bunney BG, Costa J, Gulasekaram B (1999). Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia. American Journal of Psychiatry 156, 145-147.
35. Rao ML, Gross G, Strebel B, Braunig P, Huber G, Klosterkotter J (1990). Serum amino acids, central monoamines, and hormones in drug-naive, drug-free, and neuroleptic-treated schizophrenic patients and healthy subjects. Psychiatry Research 34, 243-257.
36. Smeraldi E, Lucca A, Macciardi F, Bellodi L (1987). Increased concentrations of various amino acids in schizophrenic patients. Evidence for heterozygosity effects? Human Genetics 76, 138-140.
37. Sumiyoshi T, Hasegawa M, Jayathilake K, Meltzer HY (1997a). Prediction of short-term changes in symptom severity by baseline plasma homovanillic acid levels in schizophrenic patients receiving clozapine. Psychiatry Research 69, 113-121.
38. Sumiyoshi T, Hasegawa M, Jayathilake K, Meltzer HY (1997b). Sex differences in plasma homovanillic acid levels in schizophrenia and normal controls: relation to neuroleptic resistance. Biological Psychiatry 41, 560-566.
39. Sumiyoshi T, Jayathilake K, Meltzer HY (2003). A comparison of two doses of melperone, an atypical antipsychotic drug, in the treatment of schizophrenia. Schizophrenia Research 62, 65-72.
40. Toru M, Kurumaji A, Ishimaru M (1994). Excitatory amino acids: implications for psychiatric disorders research. Life Science 55, 1683-1699.
41. Toth E, Lajtha A (1986). Antagonism of phencyclidine-induced hyperactivity by glycine in mice. Neurochemical Research 11, 393-400.
42. Tsai G, Yang P, Chung LC, Lange N, Coyle JT (1998). D-serine added to antipsychotics for the treatment of schizophrenia. Biological Psychiatry 44, 1081-1089.
43. Tsai GE, Yang P, Chung L-C, Tsai I-C, Tsai C-W, Coyle JT (1999). D-Serine added to clozapine for the treatment of schizophrenia. American Journal of Psychiatry 156, 1822-1825.
44. Waters Associates (1984). Pico-Tag Amino Acid Analysis System. Manual No. 88140. Milford, MA: Water Associates Publication Dept.
45. Waziri R, Baruah S, Sherman AD (1993). Abnormal serine-glycine metabolism in the brains of schizophrenics. Schizophrenia Research 8, 233-243.
46. Waziri R, Mott J (1986). Drug effects on serine metabolism in psychiatric patients. Psychiatry Research 18, 119-126.
47. Waziri R, Wilcox J, Sherman AD, Mott J (1984). Serine metabolism and psychosis. Psychiatry Research 12, 121-136.
48. Waziri R, Wilson R, Sherman AD (1983). Plasma serine to cysteine ratio as a biological marker for psychosis. British Journal of Psychiatry 143, 69-73.
49. Wilcox J, Waziri R, Sherman A, Mott J (1985). Metabolism of an ingested serine load in psychotic and nonpsychotic subjects. Biological Psychiatry 20, 41-49.